ClinicalTrials.gg
RecruitingNCT07423533Updated May 22, 2026

Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD

A Phase 2 interventional study of GenSci120 150 mg and GenSci120 600 mg in Rheumatoid Arthritis, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 249 studies in Arthritis, Rheumatoid with a site in China — 63 open to participants now, 72 under way, 3 of them phase 3. Arthritis, Rheumatoid · China.

Planned enrollment
37th of 217
450 · median 134
Started
2026
with 18 others
Phase 2
34 of 249
8 open now
Primary completion
2027-09
later than 47 of 71 live
Registered
234th of 249
by date

Among the 249 studies in Arthritis, Rheumatoid with a site in China, this one is the 37th largest by planned enrollment of the 217 interventional ones that give a count, is one of 19 that started in 2026, is one of 34 in phase 2, reaches primary completion later than 47 of the 71 other live ones, and was the 234th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

63 of the 249 studies in Arthritis, Rheumatoid with a site in China are open now. Recruiting first, the newest first:

57 more — sign in →

All 63 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies in Arthritis, Rheumatoid with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, parallel, placebo- and active comparator- controlled clinical study conducted in patients with moderately to severely active RA and an inadequate response to at least one DMARD, designed to assess the efficacy and safety of GenSci120 injection in this patient population. The study consists of a screening period (≤ 4 weeks), a placebo-controlled treatment period (14 weeks), an extension treatment period (14 weeks), and a follow-up period (10 weeks), with a total of 17 scheduled visits.

Read the detailed description

This is a multicenter, randomized, double-blind, parallel, placebo- and active comparator- controlled clinical study conducted in patients with moderately to severely active RA and an inadequate response to at least one DMARD, designed to assess the efficacy and safety of GenSci120 injection in this patient population. The study consists of a screening period (≤ 4 weeks), a placebo-controlled treatment period (14 weeks), an extension treatment period (14 weeks), and a follow-up period (10 weeks), with a total of 17 scheduled visits.

Participants who meet the inclusion criteria will be randomized in a 1:1:1:1:1 ratio to the GenSci120 low dose group-150 mg (Group A), GenSci120 medium dose group-600 mg (Group B), GenSci120 high dose group-1000 mg (Group C), adalimumab group (Group D), and placebo group (Group E), with 90 participants in each group, totaling 450 participants. Among them, the proportion of participants who "have treatment experience of at least one bDMARDs or tsDMARDs" is at least 40%.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • rheumatoid arthritis
  • GenSci120
  • inadequate response to at least one DMARD
  • Programmed death receptor-1 (PD-1)
  • Regulatory T cells
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who voluntarily sign an form before the start of activities related to this study, understand the procedures and methods of this study, and are willing to strictly follow the clinical study protocol to complete this study;
  2. Male or female participants aged 18- 70 years (inclusive) when signing the informed consent form;
  3. Participants diagnosed with RA according to the 2010 RA classification criteria of the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR), with ACR functional classification Class I-III at screening;
  4. Moderately to severely active RA is defined as TJC ≥ 6 and SJC ≥ 6 at screening and baseline based on 68/66 joint counts, and ESR or C-reactive protein (CRP)/hsCRP exceeding the at screening. Joints with major surgery history will not be included in TJC and SJC;

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to any component in the GenSci120 formulation, or a history of allergic reactions to any drugs, compounds, foods, or other substances, or a history of .
  2. Any autoinflammatory disease or disease (excluding secondary Sjogren's syndrome) other than RA, including but not limited to psoriatic arthritis, inflammatory bowel disease, ankylosing spondylitis, systemic lupus erythematosus, systemic sclerosis or idiopathic inflammatory myopathy, multiple sclerosis or other central demyelinating diseases, primary Sjogren's syndrome, immunodeficiency syndrome, etc;
  3. Other joint disorders which could interfere with the assessment of joint disease activity according to the investigators' judgement, such as severe osteoarthritis;
  4. History of lymphoproliferative disorders, such as lymphoma, or presence of signs or symptoms of lymphoproliferative disorders, including abnormal lymph node enlargement or hepatosplenomegaly;
  5. Those with malignant disease or with a history of malignant disease;
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    GenSci120 150 mg

    Starting from Day 1 (Week 0), GenSci120 150 mg once every 4 weeks (Q4W) until Week 24 (3 injection points are complemented by GenSci120 simulant to maintain blindness). Starting from Week 2, adalimumab simulant until Week 26

    Drug: GenSci120 150 mg

  • Experimental
    GenSci120 600 mg

    Starting from Day 1 (Week 0), GenSci120 600 mg Q4W until Week 24 (3 injection points are complemented by GenSci120 simulant to maintain blindness). Starting from Week 2, adalimumab simulant until Week 26

    Drug: GenSci120 600 mg

  • Experimental
    GenSci120 1000 mg

    Starting from Day 1 (Week 0), GenSci120 1000 mg Q4W until Week 24. Starting from Week 2, adalimumab simulant until Week 26

    Drug: GenSci120 1000 mg

  • Active comparator
    adalimumab injection 40 mg

    Starting from Day 1 (Week 0), adalimumab injection 40 mg Q2W until Week 26 (3 injection points are complemented by GenSci120 simulant at Weeks 0, 4, 8, 12, 16, 20, and 24 to maintain blindness)

    Drug: adalimumab injection 40 mg

  • Placebo comparator
    Placebo

    Placebo-controlled treatment period: Starting from Day 1 (Week 0), GenSci120 simulant (3 injection points) Q4W until Week 12, and starting from Week 2, adalimumab simulant until Week 14. Extension treatment period: Starting from Week 16, all participants in the placebo group will receive GenSci120 600 mg Q4W until Week 24, and starting from Week 18, they will receive adalimumab simulant until Week 26

    Drug: GenSci120 600 mg · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of participants achieving the American College of Rheumatology 20% improvement criteria (ACR20) for disease activity assessment in RA from baseline after 14 weeks of administration

    Time frame: from baseline after 14 weeks of administration

Secondary outcomes

  1. Proportion of participants who meet the improvement criteria for ACR20, ACR50, and ACR70 at each visit (excluding the primary endpoint) after baseline

    Time frame: at Week 2,4,6,8,10,12,14,16,18,20,22,24,26,28,38

  2. Changes from baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (DAS28-CRP) at each post-baseline visit.

    Time frame: at Week 2,4,6,8,10,12,14,16,18,20,22,24,26,28,38

Other outcomes

  1. Changes from baseline in DAS28-erythrocyte sedimentation rate (ESR) at each post-baseline visit

    Time frame: at Week 2,4,6,8,10,12,14,16,18,20,22,24,26,28,38

  2. Changes from baseline in Clinical Disease Activity Index (CDAI) at each post-baseline visit

    Time frame: at Week 2,4,6,8,10,12,14,16,18,20,22,24,26,28,38

  3. Changes from baseline in Simplified Disease Activity Index (SDAI) scores at each post-baseline visit

    Time frame: at Week 2,4,6,8,10,12,14,16,18,20,22,24,26,28,38

  4. Changes from baseline in hsCRP levels/ESR at each post-baseline visit

    Time frame: at Week 2,4,6,8,10,12,14,16,18,20,22,24,26,28,38

  5. Proportion of participants achieving DAS28-CRP ≤ 3.2/ DAS28-ESR≤3.2/ CDAI≤10/ SDAI≤11/ DAS28-CRP<2.6/ DAS28-ESR<2.6/ CDAI≤2.8/ SDAI≤3.3/ who meet the Boolean remission criteria at baseline and each subsequent visit

    Time frame: at Week 2,4,6,8,10,12,14,16,18,20,22,24,26,28,38

  6. Changes from baseline in SJC/TJC/HAQ-DI at each post-baseline visit

    Time frame: at Week 2,4,6,8,10,12,14,16,18,20,22,24,26,28,38

  7. Changes from baseline in Patient global assessment of disease activity(PGA)at each post-baseline visit

    Time frame: at Week 2,4,6,8,10,12,14,16,18,20,22,24,26,28,38

  8. Changes from baseline in Evaluator global assessment of disease activity(EGA)at each post-baseline visit

    Time frame: at Week 2,4,6,8,10,12,14,16,18,20,22,24,26,28,38

  9. Changes from baseline in Patient's assessment of pain(VAS)at each post-baseline visit

    Time frame: at Week 2,4,6,8,10,12,14,16,18,20,22,24,26,28,38

  10. Proportion of participants with Health Assessment Questionnaire-Disability Index(HAQ-DI)improvement (decrease from baseline of at least 0.22) (at Week 12, 14, 24, 28, and 38)

    Time frame: at Week 12, 14, 24, 28, and 38

  11. Changes from baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale (at Week 12, 14, 24, 28, and 38)

    Time frame: at Week 12, 14, 24, 28, and 38

  12. Changes from baseline in severity and duration of morning stiffness at baseline and subsequent visits

    Time frame: at Week 2,4,6,8,10,12,14,16,18,20,22,24,26,28,38

  13. Safety measures such as adverse events and serious adverse events

    Time frame: at Week 2,4,6,8,10,12,14,16,18,20,22,24,26,28,38

  14. Concentration of GenSci120 in serum samples

    Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 99, Day 197, Day 267

  15. Incidence and the time of anti-drug antibody (ADA) positive and neutralizing antibody (NAb) positive (if applicable) after GenSci120 administration

    Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267

  16. Total T cell counts detected by flow cytometry, as well as the percentage changes from baseline

    Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267

  17. Regulatory T cells (Treg cells) counts detected by flow cytometry, as well as the percentage changes from baseline

    Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267

  18. Programmed death receptor-1 (PD-1) expressing total T cell counts detected by flow cytometry, as well as the percentage changes from baseline

    Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267

  19. High PD-1 expressing total T cell counts detected by flow cytometry, as well as the percentage changes from baseline

    Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267

  20. Follicular helper T cell (Tfh cell) counts detected by flow cytometry, as well as the percentage changes from baseline

    Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267

  21. Peripheral helper T cell (Tph cell) counts detected by flow cytometry, as well as the percentage changes from baseline

    Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267

  22. Total B cell counts detected by flow cytometry, as well as the percentage changes from baseline

    Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267

  23. Plasma cell counts detected by flow cytometry, as well as the percentage changes from baseline

    Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267

  24. Serum concentration and the percentage changes from baseline of Interferon-γ (IFN-γ)

    Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267

  25. Serum concentration and the percentage changes from baseline of interleukin-6 (IL-6)

    Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267

  26. Serum concentration and the percentage changes from baseline of tumor necrosis factor-α (TNF-α)

    Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267

  27. Serum concentration and the percentage changes from baseline of chemokine CXC ligand-13 (CXCL-13)

    Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267

  28. Serum concentration and the percentage changes from baseline of interleukin-21 (IL-21)

    Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267

  29. Serum concentration and the percentage changes from baseline of soluble programmed cell death receptor-1 (sPD-1)

    Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267

  30. Serum concentration and the percentage changes from baseline of soluble programmed cell death ligand-1 (sPD-L1)

    Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267

  31. Serum concentration and the percentage changes from baseline of soluble programmed cell death ligand-2 (sPD-L2)

    Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267

  32. Concentration and the percentage changes from baseline of serum amyloid A (SAA)

    Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 197, Day 267

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Sep 2027, 17 months after the start.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's planned 17 months is close to that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2026
First posted
Feb 20, 2026
StartActual
Apr 30, 2026
Primary completionEst.
Sep 2027
CompletionEst.
Dec 2028
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07423533
Responsible party
Sponsor
First posted
Feb 20, 2026
Start date
Apr 30, 2026
Primary completion
Sep 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
May 22, 2026

Study contacts

Wei WANG
Contact
wangwei13@genscigroup.com
+86 18201085833
Xi DENG
Contact
dengxi@genscigroup.com
+86 18201085833
Zhanguo LI, Doctor
study chair · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GENSCI120

Start the discussion